Adamis Pharmaceuticals Corporation Email Format

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)  is a specialty biopharmaceuticals company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI™ (naloxone) Injection product is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.  https://www.adamispharmaceuticals.com/social-media/

✕

Access Insights for Adamis Pharmaceuticals Corporation and Millions of Other Companies

Sign up for full access to Adamis Pharmaceuticals Corporation information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory